Endocrine and metabolic disorders in adolescent and adult patients born small for gestational age
Long term disorders in patients born SGA
Keywords:
SGA, short stature, metabolic syndrome, pubertyAbstract
Children born small for gestational age (SGA), defined by a birth weight and/or length standard deviation score (SDS) of < −2 based on an appropriate reference population, represent a diverse group due to multiple underlying causes of reduced growth. This classification results in a heterogeneous patient cohort. SGA children are prone to endocrinological and metabolic issues not only in childhood but also extending into adolescence and adulthood. This population faces elevated health risks, including persistent short stature, premature adrenarche, pubertal development alterations, neurocognitive problems, and metabolic syndrome. Insulin resistance emerges as a pivotal factor c nht6j7ikontributing to these metabolic complications, prominently featuring obesity, insulin resistance, hypertension, and an increased risk of type 2 diabetes mellitus in adulthood. These medium- to long-term complications significantly impact their quality of life. Growth hormone (GH) therapy for short children born SGA facilitates height normalization throughout childhood, adolescence, and into adulthood. Catch-up growth, however, correlates with heightened risks of obesity, insulin resistance, and metabolic syndrome. Conversely, those without catch-up growth tend to exhibit pronounced short stature and cognitive dysfunction. Given these determinants, comprehensive management and clinical monitoring of SGA children should commence in the neonatal period and extend into adulthood. Recognizing and addressing these challenges early in life can mitigate the long-term impact on health and well-being, emphasizing the importance of a lifelong approach to their care.
References
Cutfield W, Ayyavoo A. The Auxological and Metabolic Consequences for Children Born Small for Gestational Age. Indian J Pediatr. 2021;88(12):1235-40. doi: 10.1007/s12098-021-03897-0.
Bertino E, Di Nicola P, Varalda A, et al. Neonatal growth charts. J Matern Fetal Neonatal Med 2012 Apr:25 Suppl 1:67-9. doi: 10.3109/14767058.2012.664889.
Hokken-Koelega ACS, van der Steen M, Boguszewski M, et al. International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood. Endocr Rev. 2023;44(3):539-65. doi: 10.1210/endrev/bnad002.
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92(3):804–10. doi: 10.1210/jc.2006-2017.
Rodrígez JMR, Toda LI, López ID, et al. Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone. Sci Rep. 2023; 13(1):3135. doi: 10.1038/s41598-023-30281-z.
Netchine I, van der Steen M, López-Bermejo A, Koledova E, Maghnie M. New Horizons in Short Children Born Small for Gestational Age. Front Pediatr. 2021;13:9:655931. doi: 10.3389/ fped.2021.655931
Jaquet D, Czernichow P. Born small for gestational age: increased risk of type 2 diabetes, hypertension and hyperlipidaemia in adulthood. Horm Res. 2003; 59(Suppl. 1):131–7. doi: 10.1159/000067848.
van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS. Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study. Lancet Diabetes Endocrinol. 2017;5(12):975–85. doi: 10.1016/S2213-8587(17)30311-X.
Goedegebuure WJ, van der Steen M, de With JL, Hokken-Koelega A. Cognition, health-related quality of life, and psychosocial functioning after GH/GnRHa treatment in young adults born SGA. J Clin Endocrinol Metab. 2018; 103(11):3931–8. doi: 10.1210/jc.2018-01463.
Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. 2009;124(3):e519-31. doi: 10.1542/peds.2009-0293
Singhala A. Long-Term Adverse Effects of Early Growth Acceleration or Catch-Up Growth. Ann Nutr Metab 2017;70:236–240. doi: 10.1159/000464302
Hvidt JJ, Brix N, Ernst A, et al. Size at birth, infant growth and age at pubertal development in boys and girls. Clin Epidemiol 2019;19(11):873-883. doi: 10.2147/CLEP.S217388.
Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ. 1997;315(7104):341-7. doi: 10.1136/bmj.315.7104.341
Simon D, Léger J, Carel jc. Optimal use of growth hormone therapy for maximizing adult height in children born small for gestational age. Best Pract Res Clin Endocrinol Metab. 2008;22(3):525-37. doi: 10.1016/j.beem.2008.03.003.
Adler E, Lambert AS, Bouvattier C, et al. Determinants of Final Height in Patients Born Small for Gestational Age Treated with Recombinant Growth Hormone. Horm Res Paediatr. 2021;94(1-2):52-62. doi: 10.1159/000516557.
Van Pareren Y, Mulder P, Houdijk M et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab. 2003; 88(8): 3584–90. doi: 10.1210/jc.2002-021172.
Dahlgren J, Wikland KA & Swedish Study Group for Growth Hormone Treatment. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res. 2005; 57(2): 216–222. doi: 10.1203/01.PDR.0000148716.71231.81
Saroufim R, Fuqua JS. The Variability of Growth and Puberty in Growth Hormone-treated Children Born Small for Gestational Age. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4263-e4264. doi: 10.1210/clinem/dgac357.
Verkauskiene R, Petraitiene I, Albertsson Wikland K. Puberty in children born small for gestational age. Horm Res Paediatr. 2013;80(2):69-77. doi: 10.1159/000353759
Ibáñez L, Valls C, Ong K, Dunger DB, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab. 2006;91(6):2068–73. doi: 10.1210/jc.2005-2329.
Lem AJ, van der Kaay DC, de Ridder MA, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97(11):4096–105. doi: 10.1210/jc.2012 1987.
Ibáñez L, López-Bermejo A, Díaz M, Marcos MV. Endocrinology and gynecology of girls and women with low birth weight. Fetal Diagn The. 2011;30:243–9. doi: 10.1159/000330366.
Boonstra VH, Weber RFA, De Jong FH, Hokken-Koelega ACS. Testis function in prepubertal boys and young men born small for gestational age. Horm Res. 2008;70(6):357-363. doi: 10.1159/000161866.
Lem AJ, van der Kaay DC, Hokken-Koelega AC. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment. J Clin Endocrinol Metab. 2013;98(1):77-86. doi: 10.1210/jc.2012-2492.
Smeets CCJ, van der Steen M, Renes JS, Hokken-Koelega AC. Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study. J Clin Endocrinol Metab. 2017;102(9):3508-16. doi: 10.1210/jc.2017-00269.
Spiegel E, Shoham-Vardi I, Sergienko R, et al. The association between birth weight at term and long-term endocrine morbidity of the offspring. J Matern Fetal Neonatal Med 2019;32(16):2657-2661. doi: 10.1080/14767058.2018.1443440.
Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. JAMA. 2009;301(21):2234-42. doi: 10.1001/jama.2009.761.
Goedegebuure WJ, Van der Steen M, Smeets CCJ, Kerkhof GF, Hokken-Koelega ACS. SGA-born adults with postnatal catch-up have a persistently unfavourable metabolic health profile and increased adiposity at age 32 years. Eur J Endocrinol. 2022;187(1):15‐26. doi: 10.1530/EJE-21-1130.
Barker DJP. The Fetal and Infant Origins of Adult Disease. Brit Med J. 1990;301(6761):1111. doi: 10.1136/bmj.301.6761.1111.
Barker DJP, Hales C, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36(1):62-7. doi: 10.1007/BF00399095.
Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989; 2(8663):577-80. doi: 10.1016/s0140-6736(89)90710-1.
Leeson C, Kattenhorn M, Morley R, Lucas A, Deanfield J. Impact of low birth weight and cardiovascular risk factors on endothelial function in early adult life. Circulation. 2001;103(9):1264–8. doi: 10.1161/01.cir.103.9.1264.
R. Spector LG, Puumala SE, Carozza SE, et al. Cancer risk among children with very low birth weights. Pediatrics. 2009;124(1):96-104. doi: 10.1542/peds.2008-3069.
Hokken-Koelega ACS. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab. 2007;92(1):160-5. doi: 10.1210/jc.2006-1073.
Bannink E, van Pareren YK, Theunissen NC, Raat h, Mulder PGM, Hokken-Koelega ACS. Quality of life in adolescents born small for gestational age: Does growth hormone make a difference? Horm Res. 2005;64(4):166–74. doi: 10.1159/000088792.
Berdal EK, Wollum AEK, Hollund IMH, et al. Health-related quality of life from 20 to 32 years of age in very low birth weight individuals: a longitudinal study. Health Qual Life Outcomes 2022;20(1):136. doi: 10.1186/s12955-022-02044-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Valentina Talarico, Angela Nicoletti, Giuseppe Raiola
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
